Clinical Impact of MRI-Guided Intracavitary–Interstitial Brachytherapy in the Curative Management of Advanced-Stage Cervical Cancer
Current Oncology · 2025
DOI: 10.3390/curroncol32030136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Antje Wark und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Brachytherapy, Magnetic Resonance Imaging, Radiotherapy, Image-Guided. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study investigates the clinical efficacy of MRI-based adaptive brachytherapy (IGABT) using combined intracavitary and interstitial techniques in the curative treatment of patients with advanced cervical cancer (LACC). A retrospective analysis was conducted on 149 LACC patients treated at a single center. The therapeutic protocol included intensity-modulated external beam radiotherapy (IMRT) and IGABT. Dosimetric parameters were evaluated for relevance for local control (LC), progression-free survival (PFS), and overall survival (OS) using Kaplan–Meier estimation, Cox regression, and log-rank test. Patients predominantly presented with stage III/IV tumors (81%, FIGO 2018). The median high-risk clinical target volume (hrCTV) was 34 cm3, with a median D90% dose of 88.9 GyEQD2. At 24 months, OS, PFS, and LC rates were 86%, 57%, and 81%, respectively. FIGO stage, tumor volume, and histology were significant predictors of PFS. Higher total hrCTV doses were strongly correlated with improved LC and PFS, emphasizing the importance of precise dosimetric optimization in IGABT and confirming the critical role of IGABT in achieving very good LC rates for LACC. The reported LC rates are comparable to landmark studies, such as INTERLACE and KEYNOTE-A18. This study validates the effectiveness of MRI-guided IGABT in enhancing local tumor control in advanced-stage cervical cancer while providing insights into the prognostic implications of dosimetric parameters such as hrCTV and point A. Future research should address the persistent challenge of distant metastases by exploring the integration of novel systemic treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
- Department of Radiation Oncology, Städtisches Klinikum Karlsruhe, 76133 Karlsruhe, Germany.
- Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
- Department of Radiation Oncology, Göttingen University Hospital, 37075 Göttingen, Germany.
- Department of Radiation Oncology, Krankenhaus Barmherzige Brüder Regensburg, 93049 Regensburg, Germany.
ORCID-Profile: Antje Wark, Eva Meixner, Jürgen Debus, Nathalie Arians
Zitieren
APA
Wark, A., Hüfner, L., Meixner, E., Oelmann, J., König, L., Höne, S., Lindel, K., Debus, J., & Arians, N. (2025). Clinical Impact of MRI-Guided Intracavitary–Interstitial Brachytherapy in the Curative Management of Advanced-Stage Cervical Cancer. Current Oncology. https://doi.org/10.3390/curroncol32030136
Vancouver
Wark A, Hüfner L, Meixner E, Oelmann J, König L, Höne S, et al. Clinical Impact of MRI-Guided Intracavitary–Interstitial Brachytherapy in the Curative Management of Advanced-Stage Cervical Cancer. Current Oncology. 2025. doi:10.3390/curroncol32030136
BibTeX
@article{Wark2025,
author = {Wark, Antje and Hüfner, Laura and Meixner, Eva and Oelmann, Jan and König, Laila and Höne, Simon and Lindel, Katja and Debus, Jürgen and Arians, Nathalie},
title = {Clinical Impact of MRI-Guided Intracavitary–Interstitial Brachytherapy in the Curative Management of Advanced-Stage Cervical Cancer},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32030136}
}
EUVIMED